Quantcast

Latest Ramelteon Stories

2009-12-04 07:30:00

MORRISTOWN, N.J., Dec. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 8mg ramelteon tablets prior to the expiration of a patent owned by Takeda Pharmaceutical Company Limited. Watson's 8mg ramelteon tablet product is a...

917469fd509ba84ce2bb795a1761564a1
2009-10-23 06:50:00

U.S. drug labels often omit key information about a medicine's effectiveness and the severity of its side effects, according to a commentary written by two doctors in the New England Journal of Medicine. Such omission of data can result in some medicines appearing safer and more effective than they actually are, wrote Drs. Lisa Schwartz and Steven Woloshin of the Dartmouth Institute for Health Policy and Clinical Practice in Hanover, New Hampshire. "The most direct way that the FDA...

2008-08-18 15:05:00

SAN DIEGO, Aug. 18 /PRNewswire/ -- The next time you consider popping a pill when you have trouble nodding off, it might be worth counting sheep instead. A senior psychiatrist at the Scripps Clinic Sleep Center in San Diego, Calif. has found evidence that taking sleeping pills regularly can increase the risk of skin cancer. Daniel F. Kripke, M.D.'s article, based on a compilation of studies involving sleeping pills and cancer, has just been published in the Journal of Sleep Research. It...

2008-06-17 09:01:11

Takeda Pharmaceutical Company has announced that its wholly owned subsidiary, Takeda Global R&D Centre, has requested a re-examination of the opinion given by the Committee for Medicinal Products for Human Use of the European Medicines Agency. This request is in response to the negative opinion of May 30, 2008, in which the Committee for Medicinal Products for Human Use (CHMP) recommended the refusal of the marketing authorization in the EU for ramelteon in the treatment of patients...

2007-11-10 06:00:09

By Wade, Alan G Ford, Ian; Crawford, Gordon; McMahon, Alex D; Nir, Tali; Laudon, Moshe; Zisapel, Nava Key words: Insomnia - Melatonin - Morning alertness - Sleep latency - Sleep quality ABSTRACT Objective: Melatonin, the hormone produced nocturnally by the pineal gland, serves as a circadian time cue and sleep-anticipating signal in humans. With age, melatonin production declines and the prevalence of sleep disorders, particularly insomnia, increases. The efficacy and safety of a...

2007-01-19 15:00:57

DEERFIELD, Ill., Jan. 19 /PRNewswire/ -- Takeda Global Research & Development Center, Inc. announced that Mehmood Khan, M.D., has been named president, reporting to Dr. Masaomi Miyamoto, general manager, pharmaceutical development division, Takeda Pharmaceutical Company Limited. Formerly senior vice president of medical and scientific affairs for Takeda Pharmaceuticals North America, Inc., Dr. Khan replaces Dr. John Yates as president. Established in January 2004, Takeda Global...

2005-07-11 12:37:56

TOKYO (Reuters) - Japan's biggest drug maker, Takeda Pharmaceutical Co. Ltd, said on Monday it is on track to release a sleeping pill as early as September in the United States and may extend its use to treat Alzheimer's disease and other illnesses. The Osaka-based drug maker plans to launch its insomnia drug Ramelteon in the U.S. market in September or October, marking its entry into the central nervous system disease segment, Takeda President Yasuchika Hasegawa told an analysts' meeting....

2005-06-25 10:07:53

In trial, ramelteon helped users doze off and sleep longer HealthDay News -- The investigational drug ramelteon reduced the time it took for people with chronic insomnia to fall asleep and also increased their total sleep time, according to the results of a Phase III study sponsored by the drug's maker, Takeda Pharmaceuticals. The study also found no evidence of rebound insomnia, next-day impairments or withdrawal effects after people stopped using the drug. The U.S. Food and Drug...

2005-06-20 22:38:45

Denver, CO, June 20, 2005 "“ Ramelteon, a novel investigational compound under review with the FDA for the treatment of insomnia, reduced the time it took to fall asleep and increased total sleep time in adults with chronic insomnia, according to results from a Phase 3 study presented this week at the 19th Annual Meeting of the Associated Professional Sleep Societies (APSS). Results of the study also showed no evidence of rebound insomnia, next-day impairments or withdrawal effects due...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related